New hope for rare ovarian cancers: drug combo trial launches

NCT ID NCT05872204

Recruiting now Disease control Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing two drugs, abemaciclib and letrozole, in 100 people with rare estrogen receptor-positive ovarian cancers (low grade serous carcinoma or granulosa cell tumors). The goal is to see if the combination can shrink tumors and control the disease. Participants take both pills daily, and the study will measure how many respond and for how long.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib (Verzenios) and letrozole (Femara)
What this could lead to: If successful, this combination could offer a new treatment option for rare ovarian cancers that are hard to treat, potentially shrinking tumors and delaying progression.
What could go wrong: This is a phase 2 trial with only 100 participants, so results are preliminary. The drugs may cause side effects like fatigue or low blood cell counts, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT TYPE GRANULOSA CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

granulosa cell tumor maligant granulosa cell tumor of ovary ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT TYPE GRANULOSA CELL TUMOR LOW GRADE SEROUS OVARIAN CARCINOMA

Contacts and locations

Locations

CHU de Liège
RECRUITING

Liège, Liège, 4000, Belgium
Centre Leon Berard
RECRUITING

Lyon, Métropole de Lyon, 69008, France
Erasmus Medical Center Rotterdam
RECRUITING

Rotterdam, South Holland, 3015 GD, Netherlands
Groupe Hospitalier Diaconesses Croix Saint Simon
RECRUITING

Paris, Île-de-France Region, 75020, France
Institut Bergonie
RECRUITING

Bordeaux, Gironde, 33000, France
Institut De Cancerologie De L'Ouest
RECRUITING

Saint-Herblain, Loire-Atlantique, 44800, France
Institut De Cancerologie Strasbourg Europe
RECRUITING

Strasbourg, Bas-Rhin, 67200, France
Institut Universitaire Du Cancer Toulouse-Oncopole
RECRUITING

Toulouse, Haute-Garonne, 31059, France
UZ Gent
RECRUITING

Ghent, Oost-Vlaanderen, 9000, Belgium
UZ Leuven
RECRUITING

Leuven, Vlaams-Brabant, 3000, Belgium
University Medical Center Groningen
NOT_YET_RECRUITING

Groningen, Provincie Groningen, 9713 GZ, Netherlands
University Medical Center Utrecht
NOT_YET_RECRUITING

Utrecht, Utrecht, 3584 CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.